Key Highlights
● Humana surged $44.75 to $431.87 as most members landed in four-star plans.
● Alignment Healthcare fell $1.17 to $7.55 on a downgraded contract.
● Clover Health rose $0.21 to $4.79 after five-star PPO ratings.
● Health care was among the best S&P 500 sectors.
Every year the Centers for Medicare & Medicaid Services rates private Medicare Advantage plans on a scale of one to five stars, based on quality and member experience. Plans rated four stars or higher qualify for bonus payments, so the share of an insurer's members in highly rated plans can swing its future revenue by billions of dollars. CMS released the 2027 ratings on Thursday, October 8, and the market delivered its verdict on Friday.
Humana: the big winner
Humana (NYSE:HUM) surged $44.75 to $431.87. Nearly all of its Medicare Advantage members will be in plans rated four stars or higher, a dramatic improvement from 2026, when estimates put the share at somewhere between about a fifth and about two-fifths. CMS also restored its largest contract, H5216, to four stars from 3.5. Humana reaffirmed its 2026 adjusted earnings guidance.
J.P. Morgan (NYSE:JPM) analyst Lisa Gill called the result a "clear win for a company that has been working toward this outcome for several years". TD Cowen's Ryan Langston estimated more than $3 billion in added 2028 revenue. According to market data, Barclays (NYSE:BCS) upgraded Humana to Overweight with a $515 target, up from $407, and Cantor Fitzgerald raised its target to $460 from $300.
Alignment Healthcare: the big loser
Alignment Healthcare (NASDAQ:ALHC) fell $1.17 to $7.55 after being down far more before the open. Six of its seven eligible contracts earned four stars or more, but the one covering more than three-quarters of its members, its largest California contract, slipped to 3.5 stars from four. That means the share of members in four-star-plus plans drops from nearly all to about a quarter.
TD Cowen's Langston estimated a hit of more than $170 million to 2028 revenue. BofA cut the stock to Neutral from Buy and its target to $9 from $25, William Blair cut to Market Perform, KeyBanc lowered its target to $12 from $28 and JPMorgan to $10 from $22. Alignment disputes the rating. "We intend to pursue all available administrative remedies," said president Dawn Maroney.
CVS and UnitedHealth: mixed signals
CVS Health (NYSE:CVS), parent of Aetna, came under pressure early after its share of members in four-star-plus plans fell to roughly two-thirds from about four-fifths. CVS countered that a majority of Aetna members remain in highly rated plans, and Aetna president Steve Nelson said disciplined execution and better member care support its confidence in returning to appropriate margins.
UnitedHealth Group (NYSE:UNH) also saw its share fall to about two-thirds from roughly three-quarters, yet the stock held steady early and finished higher at about $379.30. A trade report said Elevance and Centene will also have fewer members in four-star-plus plans.
A smaller winner
Clover Health (NASDAQ:CLOV) rose $0.21 to $4.79 after CMS awarded its PPO plans five stars for 2027, with contract H-5141 moving up from 4.5.
Health care was among the best S&P 500 sectors on Friday, also helped by a rally in vaccine makers. The S&P 500 rose 46.18 points to 7,811.54.
Insurer Commentary on 2028 Payments Is the Next Signal
Alignment's administrative challenge is one item to follow. Investors will also listen for any further comments from insurers on how the ratings feed into 2028 payments. September consumer prices arrive Wednesday, October 14, and Johnson & Johnson (NYSE:JNJ) reports Tuesday, October 13. Stock markets are open on Monday, October 12, but the bond market is shut for Columbus Day. The Fed meets October 27–28.






Please wait processing your request...